Login to Your Account



Clinic Roundup


Thursday, January 13, 2011
MedImmune LLC, of Gaithersburg, Md., and Micromet Inc., of Bethesda, Md., began Phase I trials of MEDI-565 (MT111) in advanced gastrointestinal cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription